Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Cut to $210.00

Jazz Pharmaceuticals (NASDAQ:JAZZGet Free Report) had its target price reduced by analysts at Needham & Company LLC from $222.00 to $210.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price target indicates a potential upside of 94.50% from the company’s current price.

A number of other research analysts have also issued reports on JAZZ. StockNews.com lowered Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $195.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, February 29th. UBS Group decreased their price target on Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating for the company in a report on Friday, March 1st. Truist Financial reaffirmed a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. Finally, The Goldman Sachs Group assumed coverage on Jazz Pharmaceuticals in a report on Wednesday, June 5th. They set a “buy” rating and a $169.00 price target for the company. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $190.00.

Read Our Latest Research Report on JAZZ

Jazz Pharmaceuticals Trading Up 0.6 %

NASDAQ:JAZZ opened at $107.97 on Thursday. The firm has a market cap of $6.81 billion, a PE ratio of 22.26, a price-to-earnings-growth ratio of 1.73 and a beta of 0.62. The stock has a fifty day moving average price of $109.08 and a 200 day moving average price of $117.23. Jazz Pharmaceuticals has a 12-month low of $103.01 and a 12-month high of $146.70. The company has a current ratio of 2.27, a quick ratio of 1.90 and a debt-to-equity ratio of 1.38.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Free Report) last released its earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.53 by ($1.55). The company had revenue of $901.98 million during the quarter, compared to analysts’ expectations of $938.99 million. Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. Sell-side analysts anticipate that Jazz Pharmaceuticals will post 15.35 earnings per share for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $109.65, for a total transaction of $548,250.00. Following the transaction, the executive vice president now owns 36,629 shares in the company, valued at approximately $4,016,369.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in JAZZ. Rise Advisors LLC boosted its stake in shares of Jazz Pharmaceuticals by 2,255.6% during the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock worth $26,000 after acquiring an additional 203 shares in the last quarter. Cape Investment Advisory Inc. lifted its stake in Jazz Pharmaceuticals by 14,600.0% in the 4th quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock valued at $36,000 after buying an additional 292 shares in the last quarter. Covestor Ltd lifted its stake in Jazz Pharmaceuticals by 676.5% in the 3rd quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company’s stock valued at $51,000 after buying an additional 345 shares in the last quarter. Assetmark Inc. lifted its stake in Jazz Pharmaceuticals by 37.1% in the 4th quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company’s stock valued at $54,000 after buying an additional 119 shares in the last quarter. Finally, Headinvest LLC purchased a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at approximately $56,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

(Get Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Further Reading

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.